Inject Solesta: For durable efficacy up to 36 months1,2
30% increased of Responder50rate from month 3 to month 121
All three studies show durability of the treatment effect to 24 months as evidenced by proportion Responder502
The pivotal study, the only study followed to 36 months, showed durability of treatment effect to 36 months1,2
- Responder50 defined as proportion of patients with 50% reduction in the number of incontinence episodes compared to baseline, has been used to objectively evaluate response to treatments for FI in other studies2
Learn more about greater control with Solesta
Solesta Post-Market Approval P100014; 2011.
Solesta [Package Insert]. Santa Barbara, CA: Palette Life Sciences.